본문 바로가기
KERD
논문KCI 등재

Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group

김태정|이건국|심효섭|김효진|권건영|김루시아|정진행
대한병리학회|2014.02|Journal of Pathology and Translational Medicine|제48권 제1호|pp. 1-9|DOI http://dx.doi.org/10.4132/KoreanJPathol.2014.48.1.1

2

조회

0

다운로드

3

인용

0

참고문헌

키워드

GuidelineLung neoplasmsGene rearrangementAnaplastic lymphoma kinase
주제분류병리학

초록

Rearrangement of anaplastic lymphoma kinase (ALK) gene is the best predictor of response to crizotinib, an ALK tyrosine kinase inhibitor. However, the prevalence of the ALK fusion is low, so accurate patient identification is crucial for successful treatment using ALK inhibitors. Furthermore, most patients with lung cancer present with advanced-stage disease at the time of diagnosis, so it is important for pathologists to detect ALK-rearranged patients while effectively maximizing small biopsy or cytology specimens. In this review, we propose a guideline recommendation for ALK testing approved by the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists.

Abstract

Rearrangement of anaplastic lymphoma kinase (ALK) gene is the best predictor of response to crizotinib, an ALK tyrosine kinase inhibitor. However, the prevalence of the ALK fusion is low, so accurate patient identification is crucial for successful treatment using ALK inhibitors. Furthermore, most patients with lung cancer present with advanced-stage disease at the time of diagnosis, so it is important for pathologists to detect ALK-rearranged patients while effectively maximizing small biopsy or cytology specimens. In this review, we propose a guideline recommendation for ALK testing approved by the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists.

참고문헌 (55)

  1. Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)
  2. Lynch TJ, "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib", N Engl J Med, 350, pp.2129~2139 (2004)
  3. Paez JG, "EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy", Science, 304, pp.1497~1500 (2004)
  4. Pao W, "EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib", Proc Natl Acad Sci U S A, 101, pp.13306~13311 (2004)
  5. Soda M, "Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer", Nature, 448, pp.561~566 (2007)
  6. Kwak EL, "Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer", N Engl J Med, 363, pp.1693~1703 (2010)
  7. Shaw AT, "Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis", Lancet Oncol, 12, pp.1004~1012 (2011)
  8. Koivunen JP, "EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer", Clin Cancer Res, 14, pp.4275~4283 (2008)
  9. Boland JM, "Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas", Hum Pathol, 40, pp.1152~1158 (2009)
  10. Inamura K, "EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers", J Thorac Oncol, 3, pp.13~17 (2008)
  11. Paik JH, "Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization", J Thorac Oncol, 6, pp.466~472 (2011)
  12. Rodig SJ, "Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population", Clin Cancer Res, 15, pp.5216~5223 (2009)
  13. Shaw AT, "Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK", J Clin Oncol, 27, pp.4247~4253 (2009)
  14. Inamura K, "EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset", Mod Pathol, 22, pp.508~515 (2009)
  15. Sun Y, "Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases", J Clin Oncol, 28, pp.4616~4620 (2010)
  16. 김효진, "ALK rearrangement in a pure squamous cell carcinoma: the challenge of detection of ALK rearrangement", VIRCHOWS ARCHIV, 462, pp.597~599 (2013), SPRINGER
  17. Lindeman NI, "Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology", J Thorac Oncol, 8, pp.823~859 (2013)
  18. Marchetti A, "Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: a consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology", J Thorac Oncol, 8, pp.352~358 (2013)
  19. Travis WD, "International Association for the Study of Lung Cancer", American Thoracic Society, J Thorac Oncol, pp.2011, 6[DOI]
  20. Rekhtman N, "Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens", Mod Pathol, 24, pp.1348~1359 (2011)
  21. Kargi A, "The diagnostic value of TTF-1, CK 5", 6, and p63 immunostaining in classification of lung carcinomas, 2007, pp.15, 415~420
  22. Wu M, "p63 and TTF-1 immunostaining: a useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung", Am J Clin Pathol, 119, pp.696~702 (2003)
  23. Rossi G, "A reevaluation of the clinical significance of histological subtyping of non-small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments", Int J Surg Pathol, 17, pp.206~218 (2009)
  24. Rossi G, "Morphology and a limited number of immunohistochemical markers may efficiently subtype non-small-cell lung cancer", J Clin Oncol, 27, pp.e141~e142 (2009)
  25. Betz BL, "The use of stained cytologic direct smears for ALK gene rearrangement analysis of lung adenocarcinoma", Cancer Cytopathol, 121, pp.489~499 (2013)
  26. Savic S, "Detection of ALK-positive non-small-cell lung cancers on cytological specimens: high accuracy of immunocytochemistry with the 5A4 clone", J Thorac Oncol, 8, pp.1004~1011 (2013)
  27. Neat MJ, "ALK rearrangements in EBUS-derived transbronchial needle aspiration cytology in lung cancer", Cytopathology, 24, pp.356~364 (2013)
  28. Tanaka H, "Clinical application of immunocytochemical detection of ALK rearrangement on cytology slides for detection or screening of lung adenocarcinoma", Lung Cancer, 80, pp.289~292 (2013)
  29. Kim H, "Discordance between anaplastic lymphoma kinase status in primary non-small-cell lung cancers and their corresponding metastases", Histopathology, 62, pp.305~314 (2013)
  30. Boldrini L, "Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis", J Thorac Oncol, 2, pp.1086~1090 (2007)
  31. Pirker R, "Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop", J Thorac Oncol, 5, pp.1706~1713 (2010)
  32. Eberhard DA, "Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting", J Clin Oncol, 26, pp.983~994 (2008)
  33. Garrido P, "Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP)", Clin Transl Oncol, 14, pp.338~349 (2012)
  34. Camidge DR, "Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment", Clin Cancer Res, 16, pp.5581~5590 (2010)
  35. Mino-Kenudson M, "A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry", Clin Cancer Res, 16, pp.1561~1571 (2010)
  36. Conklin CM, "Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent", J Thorac Oncol, 8, pp.45~51 (2013)
  37. Minca EC, "ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH", J Mol Diagn, 15, pp.341~346 (2013)
  38. Selinger CI, "Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization", Mod Pathol, 26, pp.1545~1553 (2013)
  39. Hofman P, "Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma", Ann Oncol, 23, pp.1738~1743 (2012)
  40. Martinez P, "Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients", PLoS One, 8, pp.e52261~ (2013)
  41. Yi ES, "Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH", J Thorac Oncol, 6, pp.459~465 (2011)
  42. McLeer-Florin A, "Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study", J Thorac Oncol, 7, pp.348~354 (2012)
  43. Wang Z, "EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer", Oncology, 83, pp.248~256 (2012)
  44. Ying J, "Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma", Ann Oncol, 24, pp.2589~2593 (2013)
  45. Sun JM, "A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK", J Thorac Oncol, 7, pp.e36~e38 (2012)
  46. Jokoji R, "Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma", J Clin Pathol, 63, pp.1066~1070 (2010)
  47. Han XH, "Immunohistochemistry reliably detects ALK rearrangements in patients with advanced non-small-cell lung cancer", Virchows Arch, 463, pp.583~591 (2013)
  48. Takeuchi K, "Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts", Clin Cancer Res, 14, pp.6618~6624 (2008)
  49. Sanders HR, "Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer", Cancer Genet, 204, pp.45~52 (2011)
  50. Wong DW, "The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS", Cancer, 115, pp.1723~1733 (2009)
  51. Horn L, "EML4-ALK: honing in on a new target in non-small-cell lung cancer", J Clin Oncol, 27, pp.4232~4235 (2009)
  52. Takeuchi K, "KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer", Clin Cancer Res, 15, pp.3143~3149 (2009)
  53. Togashi Y, "KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only", PLoS One, 7, pp.e31323~ (2012)
  54. Kim H, "Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression", J Thorac Oncol, 6, pp.1359~1366 (2011)
  55. Thunnissen E, "EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations", Virchows Arch, 461, pp.245~257 (2012)

관련 논문AI추천

비소세포성 환자에서 Anaplastic Lymphoma Kinase 유전자 변이 진단검사김다운, 오현주한국보건의료기술평가학회 · 보건의료기술평가2014 · 제2권 제1호Molecular Testing of Lung Cancers김완섭, 김태정, 노미숙, 심효섭, 이건국, 장선희, 장세진, 정진행, 최윤라, 하승연, 김루시아대한병리학회 · Journal of Pathology and Translational Medicine2017 · 제51권 제3호Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group김완섭, 김태정, 박혜성, 신동훈, 심효섭, 이건국, 이창훈, 장선희, 최윤라, 김루시아, Korean Cardiopulmonary Pathology Study Group대한병리학회 · Journal of Pathology and Translational Medicine2021 · 제55권 제3호Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group김완섭, 심효섭, 이건국, 장선희, 장세진, 정순희, 정진행, 김루시아대한병리학회 · Journal of Pathology and Translational Medicine2013 · 제47권 제2호Analysis of Histologic Features Suspecting Anaplastic Lymphoma Kinase (ALK)-Expressing Pulmonary Adenocarcinoma김동원, 이희정, 최윤라, 최인호, 하상윤, 한정호대한병리학회 · Journal of Pathology and Translational Medicine2015 · 제49권 제4호Provisional Guideline Recommendation for EGFR Gene Mutation Testing in Liquid Samples of Lung Cancer Patients: A Proposal by the Korean Cardiopulmonary Pathology Study Group김완섭, 김태정, 김효진, 박혜성, 송준선, 신동훈, 심효섭, 이건국, 이창훈, 장선희, 장세진, 최윤라, 한정호, 김루시아, Korean Cardiopulmonary Pathology Study Group대한병리학회 · Journal of Pathology and Translational Medicine2019 · 제53권 제3호

이 간행물의 다른 논문 (14건)

Usual Interstitial Pneumonia with Lung Cancer: Clinicopathological Analysis of 43 Cases정만표, 이재준, 한정호, 김진국, 최인호, 전경만, 한강민, 하상윤, 송대현, 홍민의pp. 10-16Altered Expression of PTEN and Its Major Regulator MicroRNA-21 in Pulmonary Neuroendocrine Tumors하승연, 이현욱, 노미숙pp. 17-23Distribution of Human Papillomavirus 52 and 58 Genotypes, and Their Expression of p16 and p53 in Cervical Neoplasia김활웅, 이경은, 김태은pp. 24-29P2X7 Receptor Expression in Coexistence of Papillary Thyroid Carcinoma with Hashimoto’s Thyroiditis권지현, 조성진, 박혜림, 권미정, 신형식, 남은숙pp. 30-35Effects of Fixation and Storage of Human Tissue Samples on Nucleic Acid Preservation한나영, 남수경, 곽윤진, 남경한, 이혜승, 임준, 서안나pp. 36-42
원문 보기